US 11,690,806 B2
Implantable device for sustained release of a macromolecular drug compound
Christian Schneider, Hattersheim (DE)
Assigned to Celanese EVA Performance Polymers LLC, Irving, TX (US)
Filed by Celanese EVA Performance Polymers Corporation, Irving, TX (US)
Filed on May 20, 2019, as Appl. No. 16/416,328.
Claims priority of provisional application 62/675,994, filed on May 24, 2018.
Prior Publication US 2019/0358166 A1, Nov. 28, 2019
Int. Cl. A61K 9/50 (2006.01); A61K 49/04 (2006.01); A61K 38/47 (2006.01); A61K 38/39 (2006.01)
CPC A61K 9/5026 (2013.01) [A61K 9/5031 (2013.01); A61K 9/5073 (2013.01); A61K 9/5089 (2013.01); A61K 38/39 (2013.01); A61K 38/47 (2013.01); A61K 49/04 (2013.01); C12Y 304/22032 (2013.01); C12Y 304/22033 (2013.01)] 32 Claims
 
1. An implantable device for delivery of a macromolecular drug compound, the device comprising:
a core having an outer surface, wherein the core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 0.5 kDa or more, the polymer matrix containing a first ethylene vinyl acetate copolymer having a melting temperature of from about 40° C. to about 60° C. as determined in accordance with ASTM D3418-15; and
a membrane layer positioned adjacent to the outer surface of the core, wherein the membrane layer comprises a membrane polymer matrix within which the macromolecular drug compound is optionally dispersed, wherein the membrane polymer matrix contains a second ethylene vinyl acetate copolymer having a melting temperature of from about 40° C. to about 60° C. as determined in accordance with ASTM D3418-15 in combination with a hydrophilic compound, wherein the weight ratio of the second ethylene vinyl acetate copolymer to the hydrophilic compound within the membrane polymer matrix ranges from at least about 2.3 to about 99.